Critical Contrast: Clearmind Medicine (NASDAQ:CMND) vs. Sonnet BioTherapeutics (NASDAQ:SONN)

Clearmind Medicine (NASDAQ:CMND) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Clearmind Medicine and Sonnet BioTherapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clearmind Medicine	0	0	0	0	N/A
Sonnet BioTherapeutics	0	0	2	0	3.00

Sonnet BioTherapeutics has a consensus target price of $30.00, suggesting a potential upside of 391.80%. Given Sonnet BioTherapeutics’ higher probable upside, analysts clearly believe Sonnet BioTherapeutics is more favorable than Clearmind Medicine.

Valuation and Earnings

This table compares Clearmind Medicine and Sonnet BioTherapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearmind Medicine	N/A	N/A	-$8.62 million	N/A	N/A
Sonnet BioTherapeutics	$55,881.00	339.71	-$18.83 million	N/A	N/A

Clearmind Medicine has higher earnings, but lower revenue than Sonnet BioTherapeutics.

Risk & Volatility

Clearmind Medicine has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.

Insider & Institutional Ownership

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 9.4% of Sonnet BioTherapeutics shares are held by institutional investors. 2.0% of Sonnet BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Clearmind Medicine and Sonnet BioTherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clearmind Medicine	N/A	-238.73%	-102.10%
Sonnet BioTherapeutics	N/A	-398.45%	-142.16%

Summary

Clearmind Medicine beats Sonnet BioTherapeutics on 5 of the 9 factors compared between the two stocks.

About Clearmind Medicine

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

About Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.